Friday, December 4, the FDA announced that its concerns about SGLT2 inhibitors were confirmed. FDA Concludes Invokana, SGLT2 Inhibitors, Pose Serious Risks.
In May 2015, the FDA announced it was investigating the SGLT2 inhibitors (which include brands Invokana, Farxiga, Jardiance, Xigduo, and Glyxambi) for a connection to ketoacidosis (acid in the blood) and severe urinary tract infections (UTIs).
In their latest announcement on this drug class, the FDA issued new labeling requirements to include information about ketoacidosis and UTIs and how they should be prescribed and monitored.
What this Means for the Litigation
When the FDA issues an announcement confirming that a problem exists it usually is a key indicator of the validity of the claims being asserted. It’s also a sign that the drug is officially in “Stage II.”
This means that the cost of each lead and case increases as firms across the country begin looking to sign as many clients as they can. An FDA conclusion that such a problems exists is very powerful in court, and indicates scientific support.
While we are never able to know a case’s timeline until the actual day of settlement, we do have a very significant sign that the litigation is maturing and the risk is considered to be lower.
Adding SGLT2 Inhibitor Cases to Your Inventory
We are strong believers in diversifying your inventory to minimize risk and maximize profits. If you would like to invest in SGLT2 inhibitor cases, we are offering a two-week special. We can only hold our current prices that long because the market is experiencing a large influx of advertising and the cost to acquire a single case usually rises rapidly in the following weeks and months.
To discuss adding SGLT2 inhibitor cases to your inventory, fill out the form below.
When working with Gacovino Lake, you can either invest into the case for our firm to retain them using your firm’s retainer, or you can work with a top-notch trial firm that we are already working with in exchange for a participation fee.
Whether you are looking to be the lead role on litigation or not, now is an advantageous moment to expand your inventory by being involved in the SGLT2 inhibitor litigation.
Fill out the form and one of our team will contact you shortly.
Add SGLT2 Inhibitors to Your Inventory
Complete the form below and one of our team members will reach out to you to shortly.